Few clinical trials investigated the effect of so-called “urate lowering therapy” in AKI; however, for results obtained with xanthine oxidase inhibitors, it remains unclear whether these relate to inhibition of ROS or UA production [65,66]. This evidence concerns the gene XDH and acute kidney injury.